At a glance
ClinicalIndex Comparison RecordN/ACompleted· 684,815 enrolled
Drug / intervention
Alendronate +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women
In Brief
An observational study evaluating Alendronate, Etidronate, and 3 other interventions for Esophageal Cancer and 2 related conditions. Completed, enrolled 684,815 participants.
Detailed Summary
This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma
Countries--
CollaboratorsWorld Health Information Science Consultants, LLC
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionFeb 2012
TodayJul 2026
First PostedMar 1, 2010
Enrollment StartFeb 26, 2010
Primary CompletionFeb 16, 2012
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 16.3 years ago
Interventions
Alendronatedrug
Etidronatedrug
Ibandronatedrug
Risedronatedrug
Raloxifenedrug